In Vitro and In Vivo Characterization of MCT1 Inhibitor AZD3965 Confirms Preclinical Safety Compatible with Breast Cancer TreatmentZohra Benyahia(UCLouvain), Pierre Sonveaux(UCLouvain)CancersFebruary 2, 202110.3390/cancers13030569Cited by 47SaveCiteExport RISWatch citationsRelated PapersLactate Activates HIF-1 in Oxidative but Not in Warburg-Phenotype Human Tumor Cells|PLoS ONE|2012|259